Wird geladen...
The Xyrem(®) (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017
BACKGROUND: Sodium oxybate, which is approved for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy, is available in the USA only through the restricted-distribution Xyrem(®) Risk Evaluation and Mitigation Strategy Program (Xyrem REMS Program, XRP). The XRP requi...
Gespeichert in:
| Veröffentlicht in: | Drugs Real World Outcomes |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Springer International Publishing
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7984153/ https://ncbi.nlm.nih.gov/pubmed/33439474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40801-020-00223-6 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|